PD-L1 small molecule inhibitors achieve tumor immunotherapy in three main ways: 1) blocking the direct interaction between PD-1 and PD-L1, 2) inhibiting PD-L1 transcription and translation, and 3) promoting the degradation of the PD-L1 protein 56. This evidence concerns the gene CD274 and neoplasm.